Acticor Biotech SAS
EPA:ALACT.PA
0.38 (EUR) • At close September 16, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Acticor Biotech SAS |
Symbool | ALACT.PA |
Munteenheid | EUR |
Prijs | 0.375 |
Beurswaarde | 5,908,210 |
Dividendpercentage | 0% |
52-weken bereik | 0.234 - 5.78 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Gilles Avenard M.D. |
Website | https://acticor-biotech.com |
An error occurred while fetching data.
Over Acticor Biotech SAS
Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (EUR)
Cijfers zijn in miljoenen (EUR)